CYH

Rating sellAI MemoPost-earnings T+3

Community Health

As of 2026-07-24/Post-earnings T+3/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-24 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

sell

Confidence

high

Horizon

—

Key catalyst

Q3 execution against the reset operating base • 2026-10-22

Base target: $3 / p=45% prob

Biggest risk

The Q2 print showed weaker profitability despite volume growth, with unfavorable payer mix and specialist fees offsetting operating gains. Stored earnings context also cites uninsured volume, ACA disenrollment and soft elective demand; Zacks reported adjusted EPS of -$0.19 versus a -$0.18 consensus estimate (https://www.zacks.com/stock/news/2959606/community-health-q2-loss-wider-than-expected-2026-view-lowered).

Invalidation

Break below $2 or thesis failure.

What would change my mind?

Same-store admissions and adjusted admissions improved, reimbursement rates and supplemental programs provided support, quality metrics continued to improve, and the debt tender reduced secured-note principal [#SEC-8K-2026-07-22].

Research note

Recommendation

sell

Confidence

high

As of

2026-07-24

Base target

p=45%

Bull target

p=20%

Bear target

p=35%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q2 earnings underperformance and updated FY2026 outlook
Debt reduction and operating-quality improvements
Same-store admissions and adjusted admissions improved, reimbursement rates and supplemental programs provided support, quality metrics continued to improve, and the debt tender reduced secured-note principal [#SEC-8K-2026-07-22].

BearKey bullets

Divestitures reduce the revenue base and future guidance excludes potential additional divestitures [#SEC-8K-2026-07-22].
Elective surgery demand, including orthopedic and cardiac procedures, remains a key volume risk [#EARNINGS-TRANSCRIPT-2026Q2].
First-half operating cash flow was negative $209 million, while leverage and interest burden remain high [#SEC-8K-2026-07-22].

WatchKey bullets

Q3 execution against the reset operating base

Summary

High-level snapshot

Recommendation

sell

Model confidence

high

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $3 (p=45%)

Target spread vs base: +41% / -31%

Scenario probabilities

Bull Target: $4 (p=20%)Base Target: $3 (p=45%)Bear Target: $2 (p=35%)

Commentary

Post-earnings news tone is negative: coverage emphasized the guidance reduction, wider adjusted loss and operating headwinds, while Investing.com reported a 12.83% after-hours decline (https://www.investing.com/news/company-news/community-health-q2-2026-slides-volume-gains-offset-by-margin-pressure-93CH-4809594). The price remained near $2.73 by July 24. Analyst revisions and social coverage are unavailable, so missing reaction data is not positive evidence.

As of 2026-07-24 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q2 earnings underperformance and updated FY2026 outlook
Debt reduction and operating-quality improvements

Scenarios

Bull Target (Scenario probability)

$4 / p=20% prob

Base Target (Scenario probability)

$3 / p=45% prob

Bear Target (Scenario probability)

$2 / p=35% prob

Analysis 2026-07-24 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.72

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-22
Q3 execution against the reset operating base
The next checkpoint is whether same-store volume gains convert into revenue, margin and cash flow. Q2 same-store admissions rose 1.9% and adjusted admissions 2.9%, but consolidated revenue fell 9.8%, adjusted EBITDA fell 13.2%, and first-half operating cash flow was negative $209 million. Stored earnings-call context highlights uninsured/ACA disenrollment and elective-surgery softness as back-half risks [#SEC-8K-2026-07-22] [#EARNINGS-TRANSCRIPT-2026Q2].
Prob 70.00% • Move 8.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

Q2 earnings underperformance and updated FY2026 outlook
2026-07-27
Q2 net operating revenue was $2.825 billion, adjusted EBITDA was $330 million versus $380 million a year earlier, and adjusted diluted EPS was -$0.19 versus -$0.05. The company issued updated FY2026 guidance of $11.4-$11.6 billion revenue and $1.3-$1.375 billion adjusted EBITDA, citing divestitures, unfavorable payer mix and higher medical specialist fees [#8-K-2026-07-22] [#SEC-8K-2026-07-22].
Prob 95% • Move -9% • Priced-in 90%

Long-term Catalysts

Months to a year

Debt reduction and operating-quality improvements
2026-12-31
CYH used divestiture proceeds to repurchase approximately $599 million of secured-note principal. The official release also cites lower contract labor and professional-liability expenses, increased reimbursement rates and improving same-store volumes. Sustained cash generation and leverage improvement could support a rerating, but the thesis remains conditional [#8-K-2026-07-22] [#EARNINGS-TRANSCRIPT-2026Q2].
Prob 45% • Move 20% • Priced-in 45%

Risks

Divestitures reduce the revenue base and future guidance excludes potential additional divestitures [#SEC-8K-2026-07-22].
Elective surgery demand, including orthopedic and cardiac procedures, remains a key volume risk [#EARNINGS-TRANSCRIPT-2026Q2].
First-half operating cash flow was negative $209 million, while leverage and interest burden remain high [#SEC-8K-2026-07-22].
Higher medical specialist fees could offset labor and professional-liability cost controls [#SEC-8K-2026-07-22].
Unfavorable payer mix, uninsured volume and ACA exchange disenrollment may continue pressuring revenue quality and margins [#EARNINGS-TRANSCRIPT-2026Q2].

Peers

Symbol	Summary
HCA	The prior baseline noted stronger Q1 2026 revenue, adjusted EBITDA, operating cash flow and same-facility admissions than CYH, highlighting better operating momentum and balance-sheet quality.
THC	The prior baseline noted stronger Q1 2026 profitability, maintained FY2026 outlook and approximately 2.24x net leverage, leaving CYH materially more leveraged and execution-sensitive.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-24

Loading AI feed…

Symbol

Summary

HCA

The prior baseline noted stronger Q1 2026 revenue, adjusted EBITDA, operating cash flow and same-facility admissions than CYH, highlighting better operating momentum and balance-sheet quality.

THC

The prior baseline noted stronger Q1 2026 profitability, maintained FY2026 outlook and approximately 2.24x net leverage, leaving CYH materially more leveraged and execution-sensitive.